Harmony Biosciences Holdings Profit Margin

Harmony Biosciences Holdings (HRMY) currently reports a profit margin of 18.88% as of June 2026. That compares with 23.42% in the prior-year period — down 19.4% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Harmony Biosciences Holdings's profit margin history and peer comparisons.

Harmony Biosciences Holdings's profit margin decreased from 23.42% to 18.88% — a 19.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harmony Biosciences Holdings's profit margin of 18.88% is higher than the Healthcare sector average of 13.89%. That is roughly 36.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Harmony Biosciences Holdings's current 18.88% should be judged against Healthcare norms (sector average: 13.89%) and against HRMY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 18.88%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Harmony Biosciences Holdings, and consider following HRMY for alerts when major investors trade the stock.